Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Levocetirizine dihydrochloride
Drug ID BADD_D01273
Description Levocetirizine is a selective histamine H1 antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine].[L7694] Levocetirizine has greater affinity for the histamine H1 receptor than cetirizine.[L7694] Levocetirizine was granted FDA approval in 1995.[L7694]
Indications and Usage Levocetirizine is indicated for the relief of symptoms associated with allergic rhinitis (seasonal and perennial) in adults and children 6 years of age and older.
Marketing Status Prescription; OTC; Discontinued
ATC Code R06AE09
DrugBank ID DB06282
KEGG ID D08118
MeSH ID C472067
PubChem ID 9955977
TTD Drug ID D0M8PW
NDC Product Code 71335-1405; 42291-386; 81086-996; 42765-008; 69842-761; 43063-479; 51552-1415; 0363-2241; 63187-922; 71335-0940; 41250-488; 50228-136; 70518-3366; 43598-735; 0363-5529; 49574-521; 65372-1161; 62991-3149; 41167-3510; 63629-2533; 38779-2782; 73226-001; 52562-300; 43598-810; 33342-200; 71205-476; 28877-5801; 0363-3901; 28877-0090; 0363-5528; 31722-551; 51672-4161; 41163-938; 66022-0108; 71205-204; 0527-1917; 11822-0241; 53104-7644; 63629-8069; 71205-988; 69367-238; 63629-8500; 55910-241; 71205-210; 11822-5252; 17511-106; 46122-531; 76168-501; 43579-005; 30142-717; 43579-006; 49574-632; 73581-201; 42571-312; 68071-2406; 71335-1952; 10135-639; 50090-5341; 55111-282; 68788-7699; 68788-7934; 37808-126; 62207-009; 66039-939; 68071-5107; 71335-1305; 11673-847; 41167-3530; 49035-492; 70518-2797; 51927-5050; 71335-0789; 31722-659; 70000-0362; 72559-007; 68462-346; 42571-122; 71335-0418; 50090-1430; 50090-3698; 72288-241; 45802-680; 63187-663; 42543-712; 70934-835; 0536-1144; 63868-473; 50090-2591; 70518-2146; 69230-321; 0113-0241; 21130-732; 0093-7701; 72789-023; 55111-045; 36800-241
Synonyms levocetirizine | levocetrizine | acetic acid, (2-(4-((R)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)- | (2-(4-((R)-p-chloro-alpha-phenylbenzyl)-1-piperazinyl)ethoxy)acetic acid | levocetirizine hydrochloride | Xusal | levocetirizine dihydrochloride | (2-(4-((R)-(4-chlorophenyl)phenylmethyl)piperazin-1-yl)ethoxy)acetic acid dihydrochloride | cetirizine (R)-form dihydrochloride | acetic acid, (2-(4-((R)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-, dihydrochloride | Xyzal | UCB-28556
Chemical Information
Molecular Formula C21H27Cl3N2O3
CAS Registry Number 130018-87-0
SMILES C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl.Cl.Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Aggression19.05.01.001--Not Available
Agitation19.06.02.001; 17.02.05.012--
Anaphylactic reaction24.06.03.006; 10.01.07.001--
Angioedema10.01.05.009; 23.04.01.001--Not Available
Asthenia08.01.01.001--Not Available
Cholestasis09.01.01.001--Not Available
Cough22.02.03.001--
Depression19.15.01.001--
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Dry mouth07.06.01.002--
Dysgeusia17.02.07.003; 07.14.03.001--
Dyskinesia17.01.02.006--
Dyspnoea22.02.01.004; 02.01.03.002--
Dysuria20.02.02.002--
Epistaxis22.04.03.001; 24.07.01.005--
Fatigue08.01.01.002--
Fixed drug eruption23.03.05.006; 10.01.01.022; 08.01.06.017--Not Available
Glomerulonephritis20.05.01.001; 10.02.01.006--Not Available
Hallucination19.10.02.002--
Hepatitis09.01.07.004--Not Available
Hypersensitivity10.01.03.003--
Hypotension24.06.03.002--
Increased appetite14.03.01.003; 08.01.09.027--Not Available
Insomnia17.15.03.002; 19.02.01.002--
Myalgia15.05.02.001--
Nasopharyngitis22.07.03.002; 11.01.13.002--Not Available
Nausea07.01.07.001--
Oedema14.05.06.010; 08.01.07.006--Not Available
Palpitations02.01.02.003--
Paraesthesia17.02.06.005--
The 1th Page    1 2    Next   Last    Total 2 Pages